Amylin Launches Pledge Campaign to Encourage Adults with Type 2 Diabetes to Set Weekly Goals While Giving Back to Diabetes Community
<0> Amylin PharmaceuticalsNavjot RaiPhone: (858) 642-7246 </0>
Amylin Pharmaceuticals, LLC, today announced the launch of , an online pledge campaign that encourages adults with type 2 diabetes to make a difference in their own lives and in the diabetes community – one small step at a time.
This press release has an accompanying Smart Marketing Page providing further details about the organization, products and services introduced below. You can access the Smart Marketing Page via the following link: .
invites adults with type 2 diabetes to make a week-long pledge to commit to a specific behavior change that can improve their diabetes management.For each pledge, Amylin will make a $5 donation to one of four nonprofit partners, up to $25,000 each (a total donation of up to $100,000).
“For adults with type 2 diabetes, even an ordinary week demands extraordinary effort. The good news is that even small changes – like those encouraged in – can add up to better diabetes management,” said David Maggs, M.D., vice president, medical research and development, Amylin Pharmaceuticals. “ is one of the many resources Amylin has created to support and encourage adults with type 2 diabetes.”
is hosted on Diabetic Connect (hyperlink: ), a social network for people with diabetes, and participants can also share their pledges on Facebook and Twitter (#thisweekiwill) to garner added support and encouragement from their personal networks.
Amylin has partnered with the following organizations that are committed to supporting the emotional, social and educational needs of people with type 2 diabetes:
Diabetes affects nearly 26 million people in the U.S. and an estimated 347 million adults worldwide.Approximately 90-95 percent of those affected have type 2 diabetes. In the U.S., diabetes costs more than $174 billion per year in direct and indirect medical expenses.
In addition to , BYDUREON Steady Support resources are available to support the efforts of adults with type 2 diabetes. Among these resources are live phone support seven days a week, interactive tutorials online at and the option to schedule in-person sessions with a diabetes educator. Amylin is also launching bChange.com, a behavior change program developed with diabetes experts that provides an overview of “how to” successfully adopt healthy new habits and change the way patients manage their diabetes.
BYDUREON is the first and only once-weekly medicine to be approved by the FDA for the treatment of type 2 diabetes. It works by helping the body make its own insulin when needed, which may help improve glycemic control with just one dose per week. BYDUREON was approved in the U.S. in January 2012.
BYDUREON is an injectable prescription medicine that may improve blood sugar (glucose) in adults with type 2 diabetes mellitus, and should be used along with diet and exercise. BYDUREON is not recommended as the first medication to treat diabetes.
BYDUREON is a long-acting form of the medication in BYETTA(exenatide) injection so both drugs should not be used together. BYDUREON is not a substitute for insulin and has not been studied in combination with insulin. BYDUREON is not for people with type 1 diabetes or people with diabetic ketoacidosis (a condition caused by very high blood sugar). BYDUREON is not recommended for use in children. It is not known if BYDUREON is safe and effective in people with a history of pancreatitis or severe kidney problems.
Please for Medication Guide, and for US Full Prescribing Information for BYDUREON, including about possible thyroid tumors including thyroid cancer.
Amylin Pharmaceuticals, LLC, is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin is committed to delivering novel therapies that transform the way diabetes and related metabolic disorders are treated. Amylin is headquartered in San Diego, Calif. and has a commercial manufacturing facility in Ohio. More information about Amylin Pharmaceuticals is available at .
Diabetes Statistics. American Diabetes Association. Available at: . Accessed Sept. 10, 2012. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. . 2011;DOI:10.1016/S0140-6736(11)60679-X. Diabetes Overview. National Diabetes Information Clearinghouse. Available at . Accessed Sept. 10, 2012. Direct and Indirect Costs of Diabetes in the United States. American Diabetes Association. Available at: . Accessed Sept. 10, 2012.
08-12-13736-A. 09/12. ©2012 AMYLIN PHARMACEUTICALS, LLC. ALL RIGHTS RESERVED.
Photos/Multimedia Gallery Available: